- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05842707
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Primary Objectives:
--The primary objective is to determine the safety and identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of dualCAR-NK19/70 in patients with r/r B-cell lymphomas.
Hypothesis: DualCAR-NK19/70 will be safe, well-tolerated, and effective in patients with r/r B-cell lymphomas.
Secondary Objectives:
--The secondary objective is to determine the efficacy in adults with r/r LBCL and FL grade 3B treated at the MTD or RP2D of dualCAR-NK19/70. Although the clinical benefit of dualCAR-NK19/70 has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability. Secondary endpoints include overall response rate (ORR; including CR + PR) and CR rate as defined by the Lugano Classification response criteria for malignant lymphoma, DOR, PFS, and OS.
Exploratory Objectives:
--The exploratory objectives are to assess the cellular kinetics and pharmacodynamic effects of dualCAR-NK19/70 and to evaluate biomarkers associated with response, resistance, and toxicity after administration of dualCAR-NK19/70 in blood and tumor samples.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: aibin Liang
- Phone Number: 18601670600
- Email: lab7182@tongji.edu.cn
Study Contact Backup
- Name: Ping Li
- Phone Number: 13564181131
- Email: lilyforever76@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200065
- Recruiting
- Shanghai Tongji Hospital, Tongji University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily participate in the study and sign the informed consent;
- Age 18-75, male and female;
Histologically confirmed diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), and other Indolent B-cell NHL transforming types:
(A) Relapsed or Refractory DLBCL and tFL after 2 lines Immunotherapy or chemotherapy ; (B) Definition of Refractory large B cell lymphoma (SCHOLAR - 1 Research Standard) : disease progression after more than 4 courses of standard Immunotherapy or chemotherapy; Or the time of disease stabilization ≤ 6 months; Or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation (auto-HSCT); (C) Relapsed or Refractory MCL must be 1 line with immune chemotherapy; BTK inhibitors are resistant or intolerant as 2-line therapy; (D) Relapsed or Refractory disease after chemotherapy including rituximab and anthracycline.
- There was at least one measurable lesion with the longest diameter ≥ 1.5cm;
- Estimated life expectancy of more than 12 weeks other than primary disease;
- Previously confirmed diagnosis as CD19+ or CD70+ B-NHL.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.
Adequate reserve of organ function:
(A) Serum alanine aminotransferase (ALT) / aspartate aminotransferase (AST) ≤2.5 times the Upper Limit of Normal (ULN) for age; (B) A creatinine clearance (as estimated either by a direct urine collection or Cockcroft-Gault Equation) > 60mL/min; (C) Total bilirubin and alkaline phosphatase ≤1.5 times the Upper Limit of Normal (ULN) for age; (D) glomerular filtration rate > 50 ml/min (E) Cardiac ejection fraction (EF) ≥ 45% as determined by an echocardiogram (ECHO) or Multigated Radionuclide Angiography (MUGA); (F) Baseline oxygen saturation >92% on room air (G) Absolute neutrophil count > 1000/μL, Platelet count > 45,000/μL ,Hemoglobin > 80g/L;
- Once previous autologous hematopoietic stem cell transplantation (auto-HSCT) is allowed;
- For systemic therapy(Such as systemic chemotherapy, systemic radiotherapy and immunotherapy), at least 3 weeks,for Targeted drug therapy alone,at least 2 weeks,must have elapsed at the time of cell infusion;
- Either having failed or Relapsed after CAR-T therapy at 3 months of assessment;
- Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up period of the study. Women of childbearing potential must have a negative serum or urine pregnancy test.
- The viral load of severe coronavirus disease 2019 (COVID-19) is undetectable per quantitative PCR and/or nucleic acid testing for two tests.
Exclusion Criteria:
- Allergic to any of the components of cell products;
- Previous or concurrent of other type of maligant tumors;
- Acute GvHD or generalized chronic GvHD with grade II-IV (Glucksberg standard) after previous autologous hematopoietic stem cell transplantation (auto-HSCT); Or receiving of anti-GVHD therapy;
- Known history of systemic gene therapy within the prior 3 months;
- Active systemic fungal, viral, or bacterial infection (except for simple urinary tract infections and bacterial pharyngitis), however, Preventive treatment is permitted;
- Known history of infection with hepatitis B (HBsAg positive, but HBV-DNA<1000 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV infection;
- Class III or IV heart failure as defined by the New York Heart Association;
- Persisting toxicities (>grade 1, except for clinically non-significant toxicities such as alopecia, fatigue, and anorexia) due to prior trerapy;
- Known history of active seizures or presence of seizure activities or other central nervous system disease;
- Have evidence of central nervous system lymphoma(CNS lymphoma) on CT or MRI;
- Breast-feeding woman;
- Any circumstances that possibly increase the risk of subjects or interfere with study results, which judged by investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1 (dose escalation) and Part 2 (dose expansion)
Part 1 (dose escalation) the dose of dualCAR-NK19/70 participants receive will depend on when you join this study. Up to 3 dose levels of dualCAR-NK19/70 will be tested. About 3-6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level of dualCAR-NK19/70. Each new group will receive a higher dose of dualCAR-NK19/70 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of dualCAR-NK19/70 is found. Part 2 (dose expansion) Participants will receive dualCAR-NK19/70 at the recommended dose that was found in Part 1. |
Given by IV (vein)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of dose limiting toxicity(DLTs)
Time Frame: up to 28 days
|
To evaluate the safety,tolerabitility,and determine the recommended dosage of cord blood-derived CAR NK cells targeting CD19/CD70
|
up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate(ORR)
Time Frame: 6 months
|
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
|
6 months
|
Complete Remission Rate(CRR)
Time Frame: 3 months
|
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
|
3 months
|
Overall survival(OS)
Time Frame: Up to 3 years
|
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
|
Up to 3 years
|
Duration of Response(DOR)
Time Frame: Up to 3 years
|
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
|
Up to 3 years
|
progression-free survival(PFS)
Time Frame: Up to 3 years
|
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
|
Up to 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events
Time Frame: through study completion; an average of 1 year,up to 3 years
|
Type, frequency, and severity of adverse events,Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5
|
through study completion; an average of 1 year,up to 3 years
|
Exploratory Objectives
Time Frame: Up to 3 years
|
The exploratory objectives are to assess the cellular kinetics and pharmacodynamic effects of dualCAR-NK19/70 and to evaluate biomarkers associated with response, resistance, and toxicity after administration of dualCAR-NK19/70 in blood and tumor samples.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: aibin Liang, Shanghai Tongji Hospital, Tongji University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
-
920th Hospital of Joint Logistics Support Force...Gracell Biotechnology Shanghai Co., Ltd.; Kunming Hope of Health HospitalRecruitingRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B-cell Non-hodgkin LymphomaChina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Relapsed Adult ALL | Relapsed CLL | Refractory B-Cell Small Lymphocytic LymphomaUnited States
-
Janssen Research & Development, LLCCity of Hope Medical CenterRecruitingRelapsed or Refractory B Cell Non-Hodgkin LymphomaUnited States, Australia
-
Janssen Research & Development, LLCMayo ClinicRecruitingRelapsed or Refractory B Cell Non-Hodgkin LymphomaUnited States, Australia, Israel
-
AstraZenecaParexelActive, not recruitingRelapsed or Refractory B-cell Non-Hodgkin LymphomaUnited States, Korea, Republic of, Canada, United Kingdom, Spain, France, Denmark
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationRelapsed or Refractory B-cell Non-Hodgkin LymphomaChina
-
Curon Biopharmaceutical (Shanghai) Co.,LtdRecruitingRelapsed or Refractory B-Cell Non-Hodgkin LymphomaChina
-
Cellular Biomedicine Group Ltd.Tianjin Medical University Cancer Institute and HospitalUnknownRefractory or Relapsed B-cell Non-Hodgkin LymphomaChina
-
Autolus LimitedRecruitingRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin LymphomaUnited Kingdom
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
Clinical Trials on dualCAR-NK19/70 cell
-
Second Affiliated Hospital, School of Medicine,...RecruitingB-cell Non Hodgkin LymphomaChina
-
Integrative Health Technologies, Inc.Completed
-
University of Missouri-ColumbiaRecruitingMicrobial Colonization | Foot and Ankle DisordersUnited States
-
Bristol-Myers SquibbCompletedMultiple MyelomaUnited States, France, Australia
-
Netherlands Institute for Pigment DisordersCompletedLocal Anesthesia of the Skin
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted